Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.90
+0.26 (1.94%)
May 16, 2025, 10:34 AM - Market open
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $65.85M in the quarter ending March 31, 2025, with 32.84% growth. This brings the company's revenue in the last twelve months to $212.82M, up 100.03% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$212.82M
Revenue Growth
+100.03%
P/S Ratio
7.99
Revenue / Employee
$622,278
Employees
342
Market Cap
1.66B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARQT News
- 1 day ago - New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - GlobeNewsWire
- 8 days ago - Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - GlobeNewsWire
- 9 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 13 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha
- 4 weeks ago - Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - GlobeNewsWire
- 5 weeks ago - Arcutis Announces Chief Financial Officer Transition - GlobeNewsWire